1. Home
  2. SBI vs LXRX Comparison

SBI vs LXRX Comparison

Compare SBI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBI
  • LXRX
  • Stock Information
  • Founded
  • SBI 1992
  • LXRX 1995
  • Country
  • SBI United States
  • LXRX United States
  • Employees
  • SBI N/A
  • LXRX N/A
  • Industry
  • SBI Finance/Investors Services
  • LXRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBI Finance
  • LXRX Health Care
  • Exchange
  • SBI Nasdaq
  • LXRX Nasdaq
  • Market Cap
  • SBI 111.3M
  • LXRX 124.4M
  • IPO Year
  • SBI N/A
  • LXRX 2000
  • Fundamental
  • Price
  • SBI $7.78
  • LXRX $0.57
  • Analyst Decision
  • SBI
  • LXRX Buy
  • Analyst Count
  • SBI 0
  • LXRX 4
  • Target Price
  • SBI N/A
  • LXRX $3.67
  • AVG Volume (30 Days)
  • SBI 39.5K
  • LXRX 29.6M
  • Earning Date
  • SBI 01-01-0001
  • LXRX 03-06-2025
  • Dividend Yield
  • SBI 4.52%
  • LXRX N/A
  • EPS Growth
  • SBI N/A
  • LXRX N/A
  • EPS
  • SBI N/A
  • LXRX N/A
  • Revenue
  • SBI N/A
  • LXRX $31,081,000.00
  • Revenue This Year
  • SBI N/A
  • LXRX N/A
  • Revenue Next Year
  • SBI N/A
  • LXRX $101.91
  • P/E Ratio
  • SBI N/A
  • LXRX N/A
  • Revenue Growth
  • SBI N/A
  • LXRX 2481.48
  • 52 Week Low
  • SBI $6.96
  • LXRX $0.28
  • 52 Week High
  • SBI $8.00
  • LXRX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • SBI 43.09
  • LXRX 59.98
  • Support Level
  • SBI $7.75
  • LXRX $0.32
  • Resistance Level
  • SBI $7.90
  • LXRX $0.41
  • Average True Range (ATR)
  • SBI 0.05
  • LXRX 0.04
  • MACD
  • SBI -0.00
  • LXRX 0.03
  • Stochastic Oscillator
  • SBI 29.41
  • LXRX 65.92

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Share on Social Networks: